Comparative Pharmacology
Head-to-head clinical analysis: BUMEX versus LASIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUMEX versus LASIX.
BUMEX vs LASIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in normal renal function; prolonged to 2.5–4 hours in severe renal impairment (CrCl <20 mL/min).
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (CrCl <20 mL/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; total renal elimination accounts for ~85% of clearance.
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Category C
Category C
Loop Diuretic
Loop Diuretic